Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma
Condition(s):Head and Neck Squamous Cell Carcinoma; Locally Advanced OperableLast Updated:September 5, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Head and Neck Squamous Cell Carcinoma; Locally Advanced OperableLast Updated:September 5, 2023Recruiting
Condition(s):Head-and-neck Squamous Cell CarcinomaLast Updated:March 4, 2024Not yet recruiting
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:January 22, 2024Not yet recruiting
Condition(s):Metastatic Melanoma; Head and Neck Squamous Cell CarcinomaLast Updated:March 28, 2024Recruiting
Condition(s):Locally Advanced Head and Neck Squamous Cell CarcinomaLast Updated:May 6, 2023Not yet recruiting
Condition(s):Head and Neck Squamous Cell Carcinoma; Neoadjuvant ChemotherapyLast Updated:August 31, 2022Recruiting
Condition(s):Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell CarcinomaLast Updated:January 16, 2024Recruiting
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:March 21, 2024Recruiting
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:March 27, 2024Not yet recruiting
Condition(s):Head and Neck Squamous Cell Carcinomas; Resectable Head and Neck Squamous-cell CarcinomaLast Updated:February 1, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.